The European Society for Medical Oncology’s annual meeting this week featured the hottest emergent areas of cancer ...

Meet the Management at ESMO 2024 Conference September 16, 2024 2:00 PM ETCompany ParticipantsPascal Soriot - Chief ...

High response rates reported by GSK and iTeos at the 2024 European Society for Medical Oncology Congress offer a ray of light ...

The published belrestotug/dostarlimab data is still too immature to prove the combination’s capability to disrupt the NSCLC ...

More than two years after an initial FDA approval in melanoma, Bristol Myers Squibb is moving its PD-1/LAG-3 combo Opdualag ...

HK) is thrilled to unveil groundbreaking data on its internally developed ivonescimab (a first-in-class PD-1/VEGF bispecific antibody ... line treatment for PD-L1 positive (PD-L1 TPS ≥1% ...

5.82 months with pembrolizumab in 1L PD-L1 positive advanced NSCLC ... developed ivonescimab (a first-in-class PD-1/VEGF bispecific antibody) at the IASLC 2024 World Conference on Lung Cancer ...

The China-only data are impressive, signaling the PD-1/VEGF bispecific antibody’s potential ... Chinese patients with previously untreated, PD-L1-positive NSCLC. The number, presented at the ...